Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).

Roth GJ, Heckel A, Brandl T, Grauert M, Hoerer S, Kley JT, Schnapp G, Baum P, Mennerich D, Schnapp A, Park JE.

J Med Chem. 2010 Oct 28;53(20):7287-95. doi: 10.1021/jm100812a.

PMID:
20919678
2.

Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator.

Rosenbrock H, Kramer G, Hobson S, Koros E, Grundl M, Grauert M, Reymann KG, Schröder UH.

Eur J Pharmacol. 2010 Aug 10;639(1-3):40-6. doi: 10.1016/j.ejphar.2010.02.057. Epub 2010 Apr 2.

PMID:
20371241
3.

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR.

Clin Cancer Res. 2009 May 1;15(9):3094-102. doi: 10.1158/1078-0432.CCR-08-2445. Epub 2009 Apr 21.

4.

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.

Curr Biol. 2007 Feb 20;17(4):316-22. Epub 2007 Feb 8.

5.

BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.

Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR.

Biochem J. 2007 Jan 1;401(1):29-38.

6.

Synthesis and in vitro and in vivo evaluation of [11C]methyl-BIII277CL for imaging the PCP-binding site of the NMDA receptor by pet.

Kokic M, Honer M, Kessler LJ, Grauert M, Schubiger PA, Ametamey SM.

J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):123-39.

PMID:
12503611
7.

Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.

Grauert M, Bechtel WD, Weiser T, Stransky W, Nar H, Carter AJ.

J Med Chem. 2002 Aug 15;45(17):3755-64.

PMID:
12166948
8.

Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats.

Laird JM, Carter AJ, Grauert M, Cervero F.

Br J Pharmacol. 2001 Dec;134(8):1742-8.

9.

Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL.

Carter AJ, Grauert M, Pschorn U, Bechtel WD, Bartmann-Lindholm C, Qu Y, Scheuer T, Catterall WA, Weiser T.

Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4944-9.

10.
11.

N-methyl-D-aspartate receptor channel block by the enantiomeric 6,7-benzomorphans BIII 277 CL and BIII 281 CL.

Grauert M, Rho JM, Subramaniam S, Rogawski MA.

J Pharmacol Exp Ther. 1998 May;285(2):767-76.

PMID:
9580625
12.

Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as antagonists of the NMDA receptor-channel complex.

Grauert M, Bechtel WD, Ensinger HA, Merz H, Carter AJ.

J Med Chem. 1997 Aug 29;40(18):2922-30.

PMID:
9288174
13.

Comparison of serodiagnostic tests and ultrasonography for cystic hydatidosis in an epidemiological study of rural Uruguay.

Sato H, Kamiya H, Grauert MR, Stern D, Altamirano Z, Perdomo R, Carmona C, Carbó A, Alvarez C, Monti J, Sakai H, Oku Y, Kamiya M.

J Parasitol. 1996 Oct;82(5):852-4.

PMID:
8885905
14.

BIII 277 CL is a potent and specific ion-channel blocker of the NMDA receptor-channel complex.

Carter AJ, Bechtel WD, Grauert M, Harrison P, Merz H, Stransky W.

J Pharmacol Exp Ther. 1995 Dec;275(3):1382-9.

PMID:
8531106
15.

Trypanosoma cruzi infection enhances polyreactive antibody response in an acute case of human Chagas' disease.

Grauert MR, Houdayer M, Hontebeyrie-Joskowciz M.

Clin Exp Immunol. 1993 Jul;93(1):85-92.

Supplemental Content

Loading ...
Support Center